Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Depreciation (2016 - 2025)

Fate Therapeutics' Accumulated Depreciation history spans 11 years, with the latest figure at $36.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 3.09% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $36.2 million, up 3.09%, while the annual FY2025 figure was $36.2 million, 3.09% up from the prior year.
  • Accumulated Depreciation reached $36.2 million in Q4 2025 per FATE's latest filing, up from $35.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $47.6 million in Q4 2023 to a low of $16.9 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $33.3 million, with a median of $35.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation: surged 79.31% in 2022, then decreased 26.23% in 2024.
  • A 5-year view of Accumulated Depreciation shows it stood at $16.9 million in 2021, then soared by 79.31% to $30.4 million in 2022, then soared by 56.75% to $47.6 million in 2023, then decreased by 26.23% to $35.1 million in 2024, then rose by 3.09% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Accumulated Depreciation are $36.2 million (Q4 2025), $35.1 million (Q4 2024), and $47.6 million (Q4 2023).